drug

prasinezumab

1 story · latest Aug 6, 2026

Status: Investigational
Codes: PRX002, RO7046015
Trials: 3 registered trials in coverage

Relationships

Developed by Roche

Timeline

Prothena reports Q2 2026 results, updates year-end cash guidance to $259 million

Aug 6Quarterly updateProthena Corp Public Ltd Co

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.